RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery.
- Resource Type
- Article
- Authors
- Hao, Rubin; Sun, Bixi; Yang, Lihua; Ma, Chun; Li, Shuling
- Source
- Drug Delivery. Dec2020, Vol. 27 Issue 1, p772-781. 10p.
- Subject
- *BRAIN injuries
*CEREBRAL ischemia
*BRAIN damage
*NEURODEGENERATION
*CEREBRAL arteries
*NANOCAPSULES
*NANOCARRIERS
- Language
- ISSN
- 1071-7544
Effective nose-to-brain delivery needs to be developed to treat neurodegenerative diseases. Regulating miR-124 can effectively improve the symptoms of ischemic brain injury and provide a certain protective effect from brain damage after cerebral ischemia. We used rat models of middle cerebral artery occlusion (t-MCAO) with ischemic brain injury, and we delivered RVG29-NPs-miR124 intranasally to treat neurological damage after cerebral ischemia. Rhoa and neurological scores in rats treated by intranasal administration of RVG29-PEG-PLGA/miRNA-124 were significantly lower than those in PEG-PLGA/miRNA-124 nasal administration and RVG29-PLGA/miRNA-124 nasal administration group treated rats. These results indicate that the nose-to-brain delivery of PLGA/miRNA-124 conjugated with PEG and RVG29 alleviated the symptoms of cerebral ischemia-reperfusion injury. Thus, nasal delivery of RVG29-PEG-PLGA/miRNA-124 could be a new method for treating neurodegenerative diseases. [ABSTRACT FROM AUTHOR]